Sign in
Welcome! Log into your account
Forgot your password? Get helpPrivacy PolicyPassword recovery
Recover your password
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology NewsHomeTopicsBioprocessingDigitize or Fall Behind
Credit: Image generated with Google Gemini
Bioprocessing companies risk slowing scientific progress unless they embrace digital-data capture and greater collaboration, according to Alexander Seyf, CEO of Autolomous, a company developing digital manufacturing solutions for cell and gene therapies.
Speaking about the industry’s biggest challenges, Seyf describes poor data management as the “elephant in the room,” arguing that too much crucial information remains trapped in paper records, spreadsheets, and isolated systems.
“Everybody wants to have AI,” Seyf says. “But where do you have your data? If it’s in binders, there’s not much you can do.”
According to Seyf, the path toward more efficient manufacturing, stronger clinical outcomes, and meaningful AI applications begins with digitizing information from the earliest stages of research. He believes many organizations make the mistake of waiting until their science is mature before investing in digital infrastructure. “The sooner you start, the better it is,” he says. “Pen and paper do not prevail, and pen and paper do not transfer.”
Seyf argues that the consequences extend far beyond operational inefficiencies. When data remain inaccessible or fragmented, researchers lose opportunities to learn from past experiments, identify patterns, and accelerate scientific discovery. He stresses that the industry must become more willing to share non-commercially sensitive knowledge, particularly in areas such as rare diseases and advanced therapies, where patient populations are limited. “We are all here to serve patients,” he says. “Protect your intellectual property, but also share the learnings.”
One of his strongest criticisms is directed at the scientific community’s tendency to focus almost exclusively on successful outcomes. Seyf believes failed studies and unsuccessful trials often contain lessons that could prevent others from repeating the same mistakes. “A lot of publications want to publicize only the good news,” he says. “That’s fundamentally wrong. We need to learn from failures.”
To illustrate his point, Seyf compares the biotechnology sector with the aviation industry. Modern airlines routinely share information about incidents and technical problems to prevent future accidents, creating a culture of collective learning and safety. “If something goes wrong, everybody in the world knows about it and knows how it was managed,” he says. “We are also dealing with people’s lives. The only way for us to improve is to share.”
Seyf also highlights the growing role of AI in healthcare. Although consumer AI systems have benefited from vast amounts of publicly available information, healthcare still operates with a relatively small pool of accessible data, he says. Expanding that foundation, he argues, could unlock major advances in diagnosis, drug development, and personalized medicine. “Imagine what we could do,” he says. “The progression of science is unlimited.”
For commercial bioprocessors, his recommendation is straightforward: digitize from day one. Capturing research, development, manufacturing, and clinical data in digital formats not only improves collaboration but also preserves institutional knowledge when employees move on. “Every time a scientist leaves, the knowledge goes with them,” Seyf says. “But when it is digital, the knowledge stays with the company.”
As cell and gene therapies continue to evolve, Seyf believes the industry faces a choice. It can continue operating in silos, or it can embrace transparency, digitalization, and collaboration to speed innovation and deliver better outcomes for patients. “The reason humanity has progressed,” he says, “is because we shared.”
InsightsArtificial intelligenceBioprocessing methodscell therapyDrug development (Pharmacology)Gene therapy (Therapeutics)Also of Interest
CloudScope Enables Continuous Remote Monitoring of Brain Activity in Freely Moving MiceSmarter Cell Culture Starts with Better MediaCAR T Manufacturing in Japan Gets Boost from Teijin-Shinshu University Research CollaborationRevvity Signs Agreement to Acquire Human Cell DesignTop 10 Contract Development and Manufacturing Organizations 202610 CDMO Up & Comers 2026Related Media
Data Integrity as the Foundation for AISmall Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and SustainabilityBeyond the Technology: AI Readiness in Regulated LaboratoriesAACR 2026 Video Update: Cancer Research Edges Toward an AI-Driven EraReporting Live from JPM 2026: Alex Philippidis and Jonathan Grinstein, PhDAI in Protein Design: Hype vs. Reality Explained by David BakerTop 5ResourcesRecommended For YouPodcast
Touching Base
Touching Base is the dynamic podcast series from the editors ofGEN. Each episode features a rotating case of senior editors—including John Sterling, Kevin Davies, Julianna LeMieux, Alex Phillippidis, Uduak Thomas, Corinna Singleman, and Fay Lin—who delve into emerging stories, exchange ideas, and debate the latest trends in biotech. Additionally, they talk to some of the leading voices in the industry about what's now and next.Start listening today!
Stay up to date with the lasted episodes of Touching Base bysubscribing to theGENPodcast Newsletter
Copyright © 2026 Sage Publications or its affiliates, licensors, or contributors. All rights reserved, including those for text and data mining and training of large language models, artificial intelligence technologies, or similar technologies.
MORE STORIES
